Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
ADPT Stock Chart & Stats
$15.86
-$0.27(-3.80%)
At close: 4:00 PM EST
$15.86
-$0.27(-3.80%)
Day’s Range― - ―
52-Week Range$6.26 - $20.76
Previous CloseN/A
Volume480.81K
Average Volume (3M)1.94M
Market Cap
$2.42B
Enterprise Value$2.29B
Total Cash (Recent Filing)$212.77M
Total Debt (Recent Filing)$81.80M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 06, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding152,665,190
10 Day Avg. Volume2,115,559
30 Day Avg. Volume1,936,469
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)4.93
P/FCF Ratio-8.93
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue9.05
Enterprise Value/Gross Profit12.60
Enterprise Value/Ebitda-40.04
Forecast
1Y Price Target
$20.86Price Target Upside31.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Data PartnershipsNonexclusive data licensing agreements with a major pharmaceutical company validate the company's immune receptor dataset strategy and create potential for additional pharma partners and new revenue streams.
Guidance And RevenueManagement issued guidance for minimal residual disease testing that implies stronger clonoSEQ test volumes and higher average selling prices, supporting upside to revenue estimates.
Profitability And Cash FlowManagement's plan to reach positive adjusted profitability and organization-wide cash flow within its stated planning horizon reduces business risk and strengthens the investment thesis.
Bears Say
Competitive PressureAcquisition-driven market entry by a competitor has heightened investor concerns about competition in minimal residual disease testing, pressuring shares and signaling a potential shift in market dynamics.
Execution RiskAbility to meet heightened expectations for the minimal residual disease segment while progressing margins and establishing sustainable cash flow represents a material execution risk to results.
Leverage And Financial FlexibilityRising leverage and elevated net debt relative to earnings increase financial risk and could constrain strategic flexibility and investment capacity.
Adaptive Biotechnologies News
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $6.25 and its highest was $20.76 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Adaptive Biotechnologies Corp’s market cap is $2.42B.
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is May 06, 2026 which is in 83 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Feb 05, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.186 by $0.096.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -0.16.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 152,665,190 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.186. Following the earnings report the stock price went down -4.25%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Currently, no hedge funds are holding shares in ADPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adaptive Biotechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.86 (31.53% Upside)
$20.86 (31.53% Upside)
Blogger Sentiment
Neutral
ADPT Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 32.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $367.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.29%
12-Months-Change
Fundamentals
Return on Equity
-28.23%
Trailing 12-Months
Asset Growth
-4.94%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
ADPT Company Deck
ADPT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution in the MRD business: high revenue and volume growth, meaningful ASP expansion, improved gross margins and adjusted EBITDA turning positive, plus a healthy cash balance and tangible Immune Medicine data monetization. Challenges were highlighted but appear manageable: GAAP net losses remain, Immune Medicine is still loss-making though improving, some guidance depends on payer negotiations and timing, and competition and operational seasonality present risks. On balance, the company presented multiple credible levers for revenue and margin expansion and a clear path to positive free cash flow in 2026.View all ADPT earnings summariesADPT Stock 12 Month Forecast
Average Price Target
$20.86
▲(31.53% Upside)
Technical Analysis
Immunovant
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
Currently, No data available
---